Send to printer »

GEN News Highlights : Oct 26, 2006

Generic Version of Colestid Tablets Will Come to Market

Impax has 180 days of market exclusivity on its drug.
Impax Laboratories has been granted approval for its generic version of Colestid® tablets (Colestipol Hydrochloride Tablets) 1 gram. Pharmacia and Upjohn Company (Pfizer) markets these tablets as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia who haven’t responded adequately to diet.

Impax will be able to tap into brand Colestid sales, which reached $20 million for the 12 months ended August 31, 2006, in the U.S., according to Wolters Kluwer Health. The company has 180-day market exclusivity for this product as it received first-to-file status.